Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Indole-3-aldehyde for treating dysreactive immune disorders

Indole-3-aldehyde for treating dysreactive immune disorders

US Patent 10751322 · Granted Aug 25, 2020

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Thymosin alpha 1 for use in treatment of cystic fibrosis2024
Thymosin alpha 1 for use in treatment of cystic fibrosis2022
Thymosin alpha 1 for use in treatment of cystic fibrosis2019
Microencapsulation process of sertoli cells, microcapsules obtained and use for 2014
Use of IL-23 antagonists for treatment of infection2013
Treatment of Aspergillus infections with alpha thymosin peptides2013
Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for t2012
Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases2012
Treatment of Aspergillus infections with alpha thymosin peptides2012
Use of thymosin alpha 1 for the treatment of immunological diseases2011
Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases2011